Ocrevus Zunovo now approved in US to treat relapsing MS, PPMS
FDA approves Ocrevus Zunovo, a subcutaneous formulation of Ocrevus for treating MS, covering relapsing forms and primary progressive MS. This new option allows for a 10-minute injection compared to the original's 2-4 hour IV infusion, potentially increasing accessibility. Based on OCARINA II trial data, both formulations showed similar efficacy and safety, with 92% of patients satisfied with the new subcutaneous method.
Reference News
FDA approves Ocrevus Zunovo, a subcutaneous formulation of Ocrevus for treating MS, covering relapsing forms and primary progressive MS. This new option allows for a 10-minute injection compared to the original's 2-4 hour IV infusion, potentially increasing accessibility. Based on OCARINA II trial data, both formulations showed similar efficacy and safety, with 92% of patients satisfied with the new subcutaneous method.